Clinical trials
Superficial Basal Cell Carcinoma clinical trials
Below are recruiting superficial basal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 56 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06160557Enrolling by invitation
Radiation after endoscopic surgery for superficial esophageal cancer
This trial tests if adding radiation therapy after endoscopic surgery (ESD) helps people with early-stage esophageal cancer that had certain high-risk features, like deeper invasion or positive margins. It aims to improve outcomes for those who didn't get a complete cure with surgery alone.
Fuzhou, FujianAges 18–75 - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07457281RecruitingPhase 1
A new drug combo for head and neck cancer before surgery
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
ChengduAges 18–70 - NCT05978284RecruitingPhase 1/Phase 2
Study of ZG006 for small cell lung cancer or neuroendocrine carcinoma
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
Zhengzhou, HenanAges 18–75 - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Bullhead City, ArizonaAges 18 years+ - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07397611RecruitingPhase 2
Neoadjuvant immunotherapy for clear cell kidney cancer
This study tests a new combination of medications (casdatifan and zimberelimab) given before surgery to remove kidney tumors in people with clear cell renal cell carcinoma (ccRCC). The goal is to see if this approach can help shrink the tumor or improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT06223568RecruitingPhase 2
Chemotherapy with or without vaccine for HPV-related throat cancer
This trial compares standard chemotherapy alone versus chemotherapy combined with an investigational vaccine (PRGN-2009) before surgery for newly diagnosed HPV-positive oropharyngeal (throat) cancer. The goal is to see if adding the vaccine improves outcomes.
Bethesda, MarylandAges 18–120 - NCT05507411RecruitingPhase 2
Watch-and-wait after chemo-radiation plus immunotherapy for esophagus cancer
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hanzhou, ZhejiangAges 18–75 - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT07572864RecruitingPhase 2
Immunotherapy and vaccine before surgery for head and neck cancer
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
Chengdu, SichuanAges 18 years+ - NCT07565740RecruitingPhase 1
Vaccine plus immunotherapy for newly diagnosed HPV-positive throat cancer
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
Chengdu, SichuanAges 18 years+ - NCT07550972Enrolling by invitationPhase 2
Combination drug treatment before surgery for advanced head and neck cancer
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07501650RecruitingPhase 1
Pembrolizumab plus ultrasound bubbles for head and neck cancer
This trial combines the immunotherapy drug pembrolizumab (Keytruda) with a special ultrasound technique that uses tiny bubbles to make the treatment work better. It is for people with HPV-negative head and neck cancer that has come back or spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+
Hear when a new Superficial Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for superficial basal cell carcinoma?
- Yes. Clin2 currently lists 56 recruiting superficial basal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a superficial basal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a superficial basal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.